Podocyte <scp>mPGES</scp> ‐2 Determines Renal Aging and Contributes to Senile Osteoporosis

ABSTRACT Renal aging shortens healthspan and propagates organ dysfunction beyond the kidney, yet its molecular drivers remain incompletely defined. Here we identify microsomal prostaglandin E synthase‐2 (mPGES‐2) as a critical regulator of renal aging and its skeletal consequence. Genetic ablation of Ptges2 improved health indices in aged mice, prolonged median survival, and markedly alleviated glomerulosclerosis, podocyte injury, and renal senescence. Single‐cell transcriptomic analysis, together with podocyte‐ and tubule‐specific knockout models, showed that podocyte mPGES‐2, rather than tubular mPGES‐2, is the dominant intrarenal driver of aging‐related kidney injury. Mechanistically, mPGES‐2 promoted podocyte senescence through a PGE 2 /EP1 signaling axis. Podocyte‐specific Ptges2 deletion also mitigated age‐related osteoporosis and restored renal calcitriol and α‐klotho, supporting a kidney‐bone mechanism secondary to impaired renal endocrine function. Consistent with the genetic models, pharmacological inhibition of mPGES‐2 with SZ0232 attenuated renal aging and improved bone microarchitecture in aged mice. Both genetic deficiency and pharmacological inhibition of mPGES‐2 were well tolerated, with no overt adverse effects on major organs. These findings identify podocyte mPGES‐2 as a druggable determinant of renal aging and a potential therapeutic target for aging‐associated osteoporosis.